XORTX Therapeutics Inc.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $3.8M
- Market cap
- $3.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 4, 2018
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review XORTX Therapeutics Inc..